// App-Quantinova.ai

657 : Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

Researchers

Presenter

  • Andrew M. Brunner

Principal Investigators

  • Kimmo Porkka

  • Steve Knapper

  • Norbert Vey

  • Sebastian Scholl

  • Guillermo Garcia-Manero

  • Martin Wermke

  • Jeroen Janssen

  • Elie Traer

  • Sun Loo

  • Rupa Narayan

  • Natalia Tovar

  • Mika Kontro

  • Oliver Ottmann

  • Purushotham Naidu

  • Sema Kurtulus

  • Jessica Makofske

  • Serena Liao

  • Anisa Mohammed

  • Catherine A. Sabatos-Peyton

  • Mikael L. Rinne

  • Uma Borate

  • Andrew H. Wei

Medical Centers

  • Massachusetts General Hospital, Boston, MA

  • Dermatology Department, Hospital Clinic of Barcelona, Barcelona, Spain

  • Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, Helsinki, Finland

  • Cardiff University, Cardiff, United Kingdom

  • Institut Paoli-Calmettes, Marseille, France

  • Essen University Hospital, Essen, Germany

  • 1.MD Anderson Cancer Center, Houston, TX

  • University Hospital Dresden, Dresden, Germany

  • Amsterdam University Medical Center, Location VU University Medical Center, Amsterdam, Netherlands

  • Oregon Health and Science University, Portland, OR

  • The Alfred Hospital, Melbourne, Australia

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis Institutes for BioMedical Research, Inc, Cambridge, MA

  • The Alfred Hospital and Monash University, Melbourne, Australia

Locations

  • United States

  • Spain

  • Finland

  • United Kingdom

  • France

  • Germany

  • Netherlands

  • Australia

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic myelomonocytic leukemia

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

Biomarkers

  • Hormone receptor

Drug/Treatment

  • Vidaza

  • Decitabine

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT03066648

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved